Arrowhead's Warrants Delisted from Nasdaq after the Close of Business on Wednesday, June 8, 2005
June 09 2005 - 7:00AM
Business Wire
Arrowhead Research Corporation (NASDAQ:ARWR) delisted its warrants
to purchase common stock (NASDAQ:ARWRW) from The Nasdaq Stock
Market after the close of business on Wednesday, June 8, 2005, as
part of its previously announced Warrant Redemption plan. Warrant
holders may exercise their Warrants until 4:00 PM PST on Tuesday,
June 14, 2005 (the "Exercise Deadline"). The warrants are
exercisable for $1.50 per share and are redeemable at the
redemption price of $0.001 per warrant. Unless the Exercise
Deadline is extended, Warrants not properly exercised by the
Exercise Deadline will be redeemed by the Company for $0.001 per
share on Wednesday, June 15, 2005. About Arrowhead Research
Corporation Arrowhead Research Corporation is a diversified
nanotechnology company structured to commercialize products
expected to have revolutionary impacts on a variety of industries,
including materials, electronics, life sciences, and energy. There
are three strategic components to Arrowhead's business model: --
Outsourced R&D Program: Arrowhead identifies patented or
patent-pending technologies at universities or government labs and
funds additional development of those technologies in exchange for
exclusive rights to commercialize the resulting prototypes.
Leveraging the resources and infrastructure of these institutions
provides Arrowhead with a highly cost-effective development
pipeline. Currently, Arrowhead is supporting efforts in stem cell
technology, nanomaterials, nanoelectronics, and nanobiotools at the
California Institute of Technology and Stanford University. --
Commercialization Program: After prototypes have been sufficiently
developed in the laboratories, Arrowhead forms or acquires
majority-owned subsidiaries to commercialize the technology and
provides the subsidiaries with strategic, managerial, and
operational support. At present, Arrowhead owns majority interest
in subsidiaries commercializing diverse technologies, including
anti-cancer drugs, RNAi therapeutics, and compound semiconductor
materials. -- The Patent Toolbox: Arrowhead has acquired or
exclusively licensed patents and patent applications covering a
broad range of nanotechnology. The Company is actively seeking to
add to this intellectual property portfolio. Safe Harbor Statement
under the Private Securities Litigation Reform Act of 1995: This
news release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including the recent economic slowdown
affecting technology companies, the future success of our
scientific studies, our ability to successfully develop products,
rapid technological change in our markets, changes in demand for
our future products, legislative, regulatory and competitive
developments and general economic conditions. Our Annual Report on
Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on
Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and
8-K/A, our Registration Statement on Form S-3, and other SEC
filings discuss some of the important risk factors that may affect
our business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason.
Arrowhead Research (MM) (NASDAQ:ARWRW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Arrowhead Research (MM) (NASDAQ:ARWRW)
Historical Stock Chart
From Oct 2023 to Oct 2024